Neurocrine Biosciences, Inc.

As of November 21, 2025, Neurocrine Biosciences, Inc. is considered an attractive investment due to its undervalued stock, strong fundamentals with a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%, despite recent underperformance compared to the S&P 500.

As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and monthly MACD, but with caution due to mixed signals from weekly indicators and underperformance against the S&P 500 in the longer term.

As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish trend overall, supported by daily moving averages and monthly MACD, but mixed signals from weekly indicators, while it has underperformed the S&P 500 with returns of 16.16% and 14.38% over the past year and three years, respectively.

As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend supported by daily moving averages and Bollinger Bands, despite mixed short-term signals from weekly indicators and underperformance compared to the S&P 500 over various time frames.

As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and On-Balance Volume, but with caution due to mixed short-term signals and underperformance compared to the S&P 500.

As of October 24, 2025, Neurocrine Biosciences, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 recently, though it has underperformed over longer periods.

As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although it has underperformed the S&P 500 over the longer term despite a recent weekly outperformance.

As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although mixed signals from KST and Dow Theory suggest caution, while the stock has outperformed the S&P 500 in the short term but lags in longer periods.

As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 35 and underperformance over five years compared to the S&P 500, despite a recent 18.26% return over the past year.

As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade shift from fair to expensive, reflected by a high P/E ratio of 35 and mixed industry performance, despite a short-term stock return of 18.26% compared to the S&P 500's 14.08%.

As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 35 and mixed performance compared to peers, despite a recent 1-year return of 18.26% that lags behind the S&P 500's longer-term returns.

As of October 10, 2025, Neurocrine Biosciences, Inc. shows a mildly bullish technical trend, supported by bullish MACD indicators and Bollinger Bands, despite mixed signals from the KST and recent underperformance against the S&P 500.

As of October 10, 2025, Neurocrine Biosciences, Inc. shows a mildly bullish technical trend, supported by bullish MACD and moving averages, despite underperforming the S&P 500 in the short term while outperforming it over the past year.

As of October 3, 2025, Neurocrine Biosciences, Inc. has a mildly bullish technical trend, supported by bullish MACD and moving averages, despite mixed signals from KST and Dow Theory, and has underperformed the S&P 500 recently while outperforming it over the past year.

As of October 3, 2025, Neurocrine Biosciences, Inc. has a mildly bullish technical trend, supported by bullish MACD and moving averages, but tempered by mixed signals from KST and Dow Theory, while it has underperformed the S&P 500 recently but outperformed it over the past year.

As of October 3, 2025, Neurocrine Biosciences, Inc. shows a mildly bullish trend with mixed signals from indicators, having underperformed the S&P 500 recently but outperformed it over the past year.